Bio & Health / RESEARCH MAP 21
Biopharmaceuticals
How does a scientific asset become an approved and commercially viable product?
From scientific discovery to evidence and commercialization.
Scope: Innovative drug development. The US pathway is an illustrative regulatory reference; individual products and other jurisdictions require separate analysis.
Geography: US regulatory reference; not a universal approval pathway.
01 / HOW IT WORKS
Follow the value chain
DEX editorial map. Read left to right (top to bottom on mobile); companies may span several stages. Expand a stage to inspect its economics.
-
Discovery & preclinical
Research teams, biotechs and research suppliers
Develop candidates and investigate their properties before human studies.
Revenue & bottleneck — Discovery & preclinical
- Revenue models to investigate
- Research services or licensing arrangements to investigate.
- Bottleneck to test
- Does the evidence justify further development and funding?
-
Clinical evidence & review
Sponsors, trial providers and regulators
Generate human evidence and evaluate a submission for approval.
Revenue & bottleneck — Clinical evidence & review
- Revenue models to investigate
- Trial-service contracts or milestone arrangements to investigate.
- Bottleneck to test
- Are safety, efficacy and manufacturing evidence sufficient?
-
Manufacture & access
Manufacturers, commercial teams and health-system buyers
Supply approved products while maintaining quality and safety monitoring.
Revenue & bottleneck — Manufacture & access
- Revenue models to investigate
- Product sales, royalties or manufacturing services to investigate.
- Bottleneck to test
- Does approval translate into supply, access and viable net revenue?
02 / FOLLOW THE MONEY · DEX INTERPRETATION
The business-model lens
Separate scientific progress, approval and commercial success. Model development spending and potential dilution before assuming future product revenue.
03 / TEST THE THESIS · RESEARCH QUESTIONS
Signals to investigate. Risks to challenge.
Demand & adoption questions
- What unmet need would a successful product address?
- Which evidence would change clinical or purchasing decisions?
What could weaken the thesis?
- Clinical failure and manufacturing problems can change the entire thesis.
- Approval alone does not establish reimbursement or commercial demand.
04 / BUILD A WATCHLIST
Metrics worth tracking
Suggested research metrics, not measured values. Collect primary data with a date, geography and definition before making comparisons.
- Evidence milestones
- State trial phase, population and endpoints; avoid treating a milestone as guaranteed.
- Cash runway
- Test spending assumptions and funding needs under delays.
- Net realized revenue
- Distinguish actual sales from headline prices and potential markets.
05 / CHECK THE EVIDENCE
Evidence anchors & sources
These sources support the statements below. They do not validate every editorial hypothesis, imply endorsement, or refresh the explorer's market estimates.
- FDA's drug-development overview describes discovery, preclinical research, clinical research, review and post-market safety monitoring. The three cards group those activities for readability. [fda]
- The 1962 U.S. Drug Amendments strengthened the evidence of effectiveness required for new-drug approval. This is historical U.S. law, not a worldwide approval pathway. [drug-act]
- Regulator explainer
The Drug Development Process
Supports: US development and review stages; not clinical advice or evidence for a particular drug.
- Original statute · PDF
Drug Amendments of 1962, Public Law 87-781
Supports: Historical U.S. effectiveness requirement and regulatory powers; not a global or modern market-size estimate.
CONTINUE THE RESEARCH
Go from map to evidence.
The 50-industry dataset is a separate screening resource with different coverage and source limitations. Related reports retain their own dates and scope.
Educational research framework only. Not investment, legal or medical advice.